Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X:
“Five review articles to read on the plane to Chicago to be ready for the practice changes in breast oncology expected from ASCO25:
1. Review of 40 years of ADC development: how we got to where we are, what we learned along the way, where we’re headed. This may particularly help contextualize DB-09 and ASCENT-04, both expected to change practice in HER2+ and TNBC, respectively.
Title: The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Authors: Raffaele Colombo, Paolo Tarantino, Jamie R. Rich, Patricia M. LoRusso, Elisabeth G.E. de Vries
Read the Full Article.
2. Optimizing the safety of ADCs.
We’re moving towards administration of ADCs for longer and longer periods (years!). This makes it more critical then ever to proactively monitor, mitigate and manage their side effects.
Title: Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Authors: Paolo Tarantino, Biagio Ricciuti, Shan M. Pradhan, Sara M. Tolaney
3. Aiming for the cure in HER2+ metastatic breast cancer.
One major hope in the field is that, by moving T-DXd to the 1L (DB-09) we may be able to cure more patients from their metastatic disease. It’s a challenging topic, yet more relevant than ever.
Title: Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer
Authors: Paolo Tarantino, Giuseppe Curigliano, Heather A. Parsons, Nancy U. Lin, Ian Krop, Elizabeth A. Mittendorf, Adrienne Waks, Eric P. Winer, Sara M. Tolaney
Read the Full Article.
4. Dual HER2 inhibition
Two trials at ASCO25 (COMPASS-HER2 pCR, NeoCARHP) may impact our treatment of HER2+ eBC. The key question: in the presence of dual HER2 blockade, can we safely reduce the amount of neoadjuvant chemo, preserving good outcomes?
Title: Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
Authors: Adrienne G. Waks, Olga Martínez-Sáez, Paolo Tarantino, Fara Braso-Maristany, Tomás Pascual, Javier Cortés, Sara M. Tolaney, Aleix Prat
Read the Full Article.
5. Precision therapeutics for HR+ breast cancer
After 20 quiet years, the field of endocrine therapies is booming. Multiple novel SERDs may be soon available, and we may start using them earlier and better. Great review from a great group of authors.”
Title: Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Authors: Maxwell R. Lloyd, Komal Jhaveri, Kevin Kalinsky, Aditya Bardia, Seth A. Wander
Read the Full Article.
